SZLS.F Stock Overview
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
StageZero Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.039 |
| 52 Week High | CA$0.061 |
| 52 Week Low | CA$0.027 |
| Beta | 0.36 |
| 1 Month Change | 44.44% |
| 3 Month Change | 35.42% |
| 1 Year Change | -38.39% |
| 3 Year Change | -93.28% |
| 5 Year Change | -95.22% |
| Change since IPO | -99.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| SZLS.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 35.4% | -4.2% | -3.7% |
| 1Y | -38.4% | -2.0% | 20.5% |
Return vs Industry: SZLS.F underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: SZLS.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SZLS.F volatility | |
|---|---|
| SZLS.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SZLS.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SZLS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 40 | James Howard-Tripp | www.stagezerolifesciences.com |
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.
StageZero Life Sciences Ltd. Fundamentals Summary
| SZLS.F fundamental statistics | |
|---|---|
| Market cap | US$3.59m |
| Earnings (TTM) | -US$12.53m |
| Revenue (TTM) | US$2.88m |
1.2x
P/S Ratio-0.3x
P/E RatioIs SZLS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SZLS.F income statement (TTM) | |
|---|---|
| Revenue | US$2.88m |
| Cost of Revenue | US$2.85m |
| Gross Profit | US$29.99k |
| Other Expenses | US$12.56m |
| Earnings | -US$12.53m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 31, 2024
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 1.04% |
| Net Profit Margin | -434.85% |
| Debt/Equity Ratio | -15.0% |
How did SZLS.F perform over the long term?
See historical performance and comparison